Wienke J, et al. - Authors examined 125 individuals to analyze galectin-9 and CXCL10 as biomarkers for disease activity, disease-specificity, and their capability to prognosticate the flares of juvenile dermatomyositis (JDM). They considered galectin-9 and CXCL10 as compared to marker creatine kinase (CK) in identifying JDM cases with active disease and remission, both cross-sectionally and longitudinally. They observed sensitivity and specificity 0.84 and 0.92 for galectin-9, and 0.87 and 1.00 for CXCL10, respectively. A continuous elevation or rise in biomarker levels suggested an imminent flare up to various months before symptoms, even in absence of elevated CK in 10 candidates. They suggested a differentiation between active disease and remission in adults with (dermato)myositis with the help of galectin-9 and CXCL10 and hence were suitable for measurement in minimally-invasive dried blood spots.